Similar articles for PMID: 28415602

Year	Number of Results
2001	1
2004	1
2005	3
2006	2
2007	3
2008	11
2009	11
2010	19
2011	18
2012	19
2013	20
2014	19
2015	12
2016	11
2017	9
2018	5
2019	5
2020	11
2021	15
2022	11
2023	5
2024	0

1

ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.

Qi L, Zhang B, Zhang S, Ci X, Wu Q, Ma G, Luo A, Fu L, King JL, Nahta R, Dong JT. Qi L, et al. Oncotarget. 2017 May 30;8(22):36054-36066. doi: 10.18632/oncotarget.16425. Oncotarget. 2017. PMID: 28415602 Free PMC article.

2

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.

Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, Harris J, Spector NL. Xia W, et al. Proc Natl Acad Sci U S A. 2006 May 16;103(20):7795-800. doi: 10.1073/pnas.0602468103. Epub 2006 May 8. Proc Natl Acad Sci U S A. 2006. PMID: 16682622 Free PMC article.

3

BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.

Godinho MF, Wulfkuhle JD, Look MP, Sieuwerts AM, Sleijfer S, Foekens JA, Petricoin EF 3rd, Dorssers LC, van Agthoven T. Godinho MF, et al. Br J Cancer. 2012 Sep 4;107(6):947-55. doi: 10.1038/bjc.2012.351. Epub 2012 Aug 14. Br J Cancer. 2012. PMID: 22892392 Free PMC article.

4

Role of ERRF, a novel ER-related nuclear factor, in the growth control of ER-positive human breast cancer cells.

Su D, Fu X, Fan S, Wu X, Wang XX, Fu L, Dong XY, Ni JJ, Fu L, Zhu Z, Dong JT. Su D, et al. Am J Pathol. 2012 Mar;180(3):1189-1201. doi: 10.1016/j.ajpath.2011.11.025. Am J Pathol. 2012. PMID: 22341523 Free PMC article.

5

Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.

Formisano L, Nappi L, Rosa R, Marciano R, D'Amato C, D'Amato V, Damiano V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani B, Parsons SJ, De Placido S, Bianco R. Formisano L, et al. Breast Cancer Res. 2014 May 5;16(3):R45. doi: 10.1186/bcr3650. Breast Cancer Res. 2014. PMID: 24887236 Free PMC article.

6

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.

Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R. Wang YC, et al. Breast Cancer Res. 2011;13(6):R121. doi: 10.1186/bcr3067. Epub 2011 Nov 28. Breast Cancer Res. 2011. PMID: 22123186 Free PMC article.

7

Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.

Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, Liewehr DJ, Steinberg SM, Merino MJ, Rubin SD, Steeg PS. Gril B, et al. J Natl Cancer Inst. 2008 Aug 6;100(15):1092-103. doi: 10.1093/jnci/djn216. Epub 2008 Jul 29. J Natl Cancer Inst. 2008. PMID: 18664652 Free PMC article.

8

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.

Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F. Valabrega G, et al. Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9. Breast Cancer Res Treat. 2011. PMID: 21153051

9

Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.

Canfield K, Li J, Wilkins OM, Morrison MM, Ung M, Wells W, Williams CR, Liby KT, Vullhorst D, Buonanno A, Hu H, Schiff R, Cook RS, Kurokawa M. Canfield K, et al. Cell Cycle. 2015;14(4):648-55. doi: 10.4161/15384101.2014.994966. Cell Cycle. 2015. PMID: 25590338 Free PMC article.

10

Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.

Cruickshanks N, Hamed HA, Booth L, Tavallai S, Syed J, Sajithlal GB, Grant S, Poklepovic A, Dent P. Cruickshanks N, et al. Cancer Biol Ther. 2013 Oct 1;14(10):982-96. doi: 10.4161/cbt.26234. Epub 2013 Aug 22. Cancer Biol Ther. 2013. PMID: 24025251 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

194 results

Results by year